European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
January 18 2024 - 4:05PM
Business Wire
Exelixis, Inc. (Nasdaq: EXEL) today announced it has
successfully defended European Patent number EP2593090 (c-MET
Modulator Pharmaceutical Compositions) against three opponents,
STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd., and
Generics (U.K.) Ltd. in a hearing before the Opposition Division of
the European Patent Office (EPO). The three-member panel of the
Opposition Division rejected all grounds of opposition, thus
upholding the patent as granted. The patent at issue, which expires
on July 18, 2031, covers tablet formulations of cabozantinib,
including the tablet formulation approved as CABOMETYX®
(cabozantinib) tablets by the European Medicines Agency. The
decision is specific to the European patent at issue and is subject
to appeal to the EPO Technical Boards of Appeal.
About Exelixis
Exelixis is a globally ambitious oncology company innovating
next-generation medicines and regimens at the forefront of cancer
care. Powered by drug discovery and development excellence, we are
rapidly evolving our product portfolio to target an expanding range
of tumor types and indications with our clinically differentiated
pipeline of small molecules, antibody-drug conjugates and other
biotherapeutics. This comprehensive approach harnesses decades of
robust investment in our science and partnerships to advance our
investigational programs and extend the impact of our flagship
commercial product, CABOMETYX® (cabozantinib). Exelixis is driven
by a bold scientific pursuit to create transformational treatments
that give more patients hope for the future. For information about
the company and its mission to help cancer patients recover
stronger and live longer, visit www.exelixis.com, follow
@ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and
follow Exelixis on LinkedIn.
Exelixis Forward-Looking Statements
This press release contains forward-looking statements,
including, without limitation, statements related to the outcome of
the EPO ruling and the potential for appeal of the EPO decision.
Any statements that refer to expectations, projections or other
characterizations of future events or circumstances are
forward-looking statements and are based upon Exelixis’ current
plans, assumptions, beliefs, expectations, estimates and
projections. Forward-looking statements involve risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in the forward-looking statements
as a result of these risks and uncertainties, which include,
without limitation, the factors detailed from time to time under
the caption “Risk Factors” in Exelixis’ most recent Annual Report
on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in
Exelixis’ other future filings with the Securities and Exchange
Commission. All forward-looking statements in this press release
are based on information available to Exelixis as of the date of
this press release, and Exelixis undertakes no obligation to update
or revise any forward-looking statements contained herein, except
as required by law.
Exelixis, the Exelixis logo and CABOMETYX are
registered U.S. trademarks of Exelixis.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240118836827/en/
Exelixis Investors Contact: Susan Hubbard EVP, Public
Affairs and Investor Relations (650) 837-8194 shubbard@exelixis.com
Exelixis Media Contact: Claire McConnaughey Senior Director,
Public Affairs (650) 837-7052 cmcconn@exelixis.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2023 to Apr 2024